Clinical trial
A Study of the Pharmacokinetics of Atazanavir (ATV)/Ritonavir(RTV) Administered as Part of Highly Active Antiretroviral Therapy (HAART) in HIV-1 Infected Pregnant Women
NCT00326716 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of the Pharmacokinetics of Atazanavir (ATV)/Ritonavir(RTV) Administered as Part of Highly Active Antiretroviral Therapy (HAART) in HIV-1 Infected Pregnant Women
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2006
- Completion date
- August 31, 2009
- Enrollment
- 69 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
hiv infection